Bronchopulmonary Dysplasia Starts in Utero: MicroRNA Dysregulation Across the Fetal-Neonatal Continuum in the Bronchopulmonary Dysplasia Development.
6 affiliations
- 1Neonatology Unit, Department of Medicine and Surgery, University of Parma, Pietro Barilla Children's Hospital, Parma, Italy.
- 2Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
- 3Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
- 4Neonatology and Intensive Care Unit, Policlinico Foggia Hospital, Foggia, Italy.
- 5Neonatal and Pediatric Intensive Care Unit, Department of Human Pathology of the Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.
- 6Neonatology Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.
Abstract
Bronchopulmonary dysplasia (BPD) is a heterogeneous developmental lung disorder resulting from the interaction between antenatal susceptibility and postnatal injury. Increasing evidence suggests that its biological origins may precede preterm birth, with placental dysfunction, fetal growth restriction, inflammation and oxidative stress influencing pulmonary developmental trajectories before exposure to the extrauterine environment. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression at the post-transcriptional level, are emerging as potential molecular mediators linking these fetal and neonatal processes. This educational review examines miRNA dysregulation across the fetal-neonatal continuum of BPD. We first discuss the role of miRNAs in physiological lung development and their disruption following premature birth. We then explore how placental dysfunction and fetal growth restriction may influence miRNA networks, including placenta-enriched C19MC miRNAs, thereby contributing to antenatal susceptibility to BPD. Particular attention is given to miRNA-mediated regulation of pulmonary angiogenesis and VEGF signaling and to the bidirectional relationship between miRNAs and oxidative stress, including modulation of NRF2-dependent antioxidant responses. Beyond their mechanistic relevance, miRNAs offer potential translational opportunities. Their stability and detectability across different biological compartments-including placenta, cord blood, peripheral blood, respiratory samples and extracellular vesicles-make them attractive candidates for longitudinal biomarker profiling, while experimental modulation using miRNA mimics and inhibitors provides proof of concept for future therapeutic approaches. However, heterogeneity in biological sampling, analytical methods, developmental timing and BPD phenotypes, together with challenges in tissue-specific delivery and off-target effects, currently limit clinical translation. Rather than identifying a single 'BPD miRNA', future research should focus on dynamic, multi-compartment miRNA networks integrating antenatal programming with postnatal exposures. Such an approach may improve molecular endotyping, early risk stratification and ultimately the development of individualized preventive and therapeutic strategies for BPD.
Related
- FOXF1 and alveolar-vascular dysregulation in bronchopulmonary dysplasia-associated pulmonary hypertension.
- Integrative transcriptomic and functional profiling reveals neutrophil-associated immune dysregulation in bronchopulmonary dysplasia.
- Bovine milk-derived osteopontin attenuates hyperoxia-induced lung injury associated with NLRP3 inflammasome regulation in neonatal mice with bronchopulmonary dysplasia
- Toward Endotype-Based Bronchopulmonary Dysplasia: Evolving Definitions and the Role of Translational Models
- Renal outcome at 2 years in neonates with nephrocalcinosis and bronchopulmonary dysplasia: a case-control study.
BibTeX
@article{perrone2026bronchopulmonary,
title = {{Bronchopulmonary Dysplasia Starts in Utero: MicroRNA Dysregulation Across the Fetal-Neonatal Continuum in the Bronchopulmonary Dysplasia Development.}},
author = {Serafina Perrone and Silvia Carloni and Virginia Beretta and Vincenzo Raitano and Pietro Leuratti and Luca Buttarelli and Elisa Caselli and Sofia Gerevini and Maria Cristina Albertini and Serena Benedetti and Francesco Nonnis-Marzano and Gianfranco Maffei and Eloisa Gitto and Giovanni Vento},
journal = {Journal of cellular and molecular medicine},
year = {2026},
month = nov,
doi = {10.1111/jcmm.71427},
url = {https://europepmc.org/article/MED/42972992},
note = {CC BY},
}
RIS
TY - JOUR
TI - Bronchopulmonary Dysplasia Starts in Utero: MicroRNA Dysregulation Across the Fetal-Neonatal Continuum in the Bronchopulmonary Dysplasia Development.
AU - Serafina Perrone
AU - Silvia Carloni
AU - Virginia Beretta
AU - Vincenzo Raitano
AU - Pietro Leuratti
AU - Luca Buttarelli
AU - Elisa Caselli
AU - Sofia Gerevini
AU - Maria Cristina Albertini
AU - Serena Benedetti
AU - Francesco Nonnis-Marzano
AU - Gianfranco Maffei
AU - Eloisa Gitto
AU - Giovanni Vento
PY - 2026
DA - 2026/11/01
JO - Journal of cellular and molecular medicine
DO - 10.1111/jcmm.71427
UR - https://europepmc.org/article/MED/42972992
AB - Bronchopulmonary dysplasia (BPD) is a heterogeneous developmental lung disorder resulting from the interaction between antenatal susceptibility and postnatal injury. Increasing evidence suggests that its biological origins may precede preterm birth, with placental dysfunction, fetal growth restriction, inflammation and oxidative stress influencing pulmonary developmental trajectories before exposure to the extrauterine environment. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression at the post-transcriptional level, are emerging as potential molecular mediators linking these fetal and neonatal processes. This educational review examines miRNA dysregulation across the fetal-neonatal continuum of BPD. We first discuss the role of miRNAs in physiological lung development and their disruption following premature birth. We then explore how placental dysfunction and fetal growth restriction may influence miRNA networks, including placenta-enriched C19MC miRNAs, thereby contributing to antenatal susceptibility to BPD. Particular attention is given to miRNA-mediated regulation of pulmonary angiogenesis and VEGF signaling and to the bidirectional relationship between miRNAs and oxidative stress, including modulation of NRF2-dependent antioxidant responses. Beyond their mechanistic relevance, miRNAs offer potential translational opportunities. Their stability and detectability across different biological compartments-including placenta, cord blood, peripheral blood, respiratory samples and extracellular vesicles-make them attractive candidates for longitudinal biomarker profiling, while experimental modulation using miRNA mimics and inhibitors provides proof of concept for future therapeutic approaches. However, heterogeneity in biological sampling, analytical methods, developmental timing and BPD phenotypes, together with challenges in tissue-specific delivery and off-target effects, currently limit clinical translation. Rather than identifying a single 'BPD miRNA', future research should focus on dynamic, multi-compartment miRNA networks integrating antenatal programming with postnatal exposures. Such an approach may improve molecular endotyping, early risk stratification and ultimately the development of individualized preventive and therapeutic strategies for BPD.
SN - 1582-1838
SN - 1582-4934
ER -